Update launch ChondroCelect (Tigenix) and status of reimbursement applications http://tiny.cc/FRRhS
posted 1 day ago
Reports, presentations and many other documents are downloadable and give detailed information about the life sciences sector and FlandersBio. FlandersBio members can contact us for more customised information prepared by our in-house experts.
Here you can download the FlandersBio corporate flyer, with more information about our goals and activities.
Flanders is home to more than 135 life sciences companies with biotech activities. In total, they employ more than 13 000 people. The biotech sector ranks 3rd for R&D investments in Flanders.
Flanders offers many assets to startup your life sciences business: academic excellene, strong life sciences innovation track, extensive life sciences facilities, strong capital,...
This brochure gives a clear overview of the financing sources on which companies can rely for the start-up or development of their company. This document is only available in Dutch and only consultable by FlandersBio member organisations.
Here you can find an overview of interesting contact details as an amendment to the brochure Subsidies and capital. This document is only available in Dutch and only consultable by FlandersBio member organisations.
Here you can find a clear overview of capital and credit suppliers as an amendment to the brochure Subsidies and capital. This document is only available in Dutch and only consultable by FlandersBio member organisations.
This brochure, made by Flanders Investment & Trade (FIT) in collaboration with FlandersBio, provides an overview of how Flanders offers life sciences companies a long and successful tradition in discovery and development, and production and logistics.
Cinbios is the Cluster of Industrial Biotech Solutions. More info can be found in this brochure or on www.cinbios.be. This flyer is only available in Dutch.
Private investements in biotech R&D reached €550 million in 2007. In addition, multiple private VC funds are available.
If you use the FlandersBio logo in your PowerPoint presentation or any other document, please let us know (jonas.debacker@flandersbio.be). We can also provide you with a high resolution for print.
In this report, from the Dutch COGEM, you can find a detailed analysis of the fast developments in biotechnology. This report is only available in Dutch.
On 1 December 2009, the new Belgian legislation on the procurement and use of human cells and tissues entered into force. As a consequence, Belgium has satisfied the requirement to transpose into Belgian law Directive 2004/23/EC of the European Parliament and European Council of 31 March 2004.
This will ensure that Belgian legislation takes into better account the recent scientific developments in molecular and cellular biotechnology that permit innovations in treatment such as gene therapy, somatic cell therapy and tissue engineering.
A small and specialised sector of research-intensive SMEs in the biotechnology industry focuses on the discovery and development of innovative biopharmaceutical medicines for human healthcare. Within the last 10-15 years, this biopharmaceutical sector has become one of the most research-intensive sectors with a great potential for delivering innovative human medicines in the future.
This Special Report provides a comprehensive overview of signifcant trends in the life Sciences presented at the congress and offers impressions of the atmosphere in the sessions, in the exhibition and at the official reception.
FlandersBio was one of the partners in making this special about innovation that appeared together with the Belgian quality newspaper De Standaard in October 2009. This special is only available in Dutch.
FlandersBio was one of the partners in making this biotech special that appeared together with the Belgian quality newspaper De Standaard in April 2009. This special is only available in Dutch.
